Should you buy Amphastar P stock now?
The technical signal for Amphastar P is currently NEUTRAL. Amphastar P trades at $19.73 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 0.141 with rising momentum (signal: 0.053); RSI is at 54.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $22.00 points to 11.5% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Amphastar P stock?
The average analyst price target for Amphastar P is $22.00. The current price is $19.73, which gives an upside of 11.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $19.80 and $24.20.
Is Amphastar P a dividend stock?
No, Amphastar P does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Amphastar P stock?
Amphastar P is rated as a stock with high risk. the annual standard deviation is 55.2%, which classifies the stock as high risk.
Is Amphastar P overvalued?
No, Amphastar P is considered undervalued based on the analyst price target (11.5% upside). Amphastar P has the following valuation ratios: a P/E ratio of 11.8 (moderately valued), a P/S ratio of 1.2, a P/B ratio of 1.1. The analyst price target suggests that the stock is undervalued by 11.5%.
Is Amphastar P overbought?
No, Amphastar P is not overbought. RSI is at 54.6 (neutral zone). The technical indicators show: RSI is at 54.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.8% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Amphastar P earnings report?
Amphastar P reports earnings TODAY, August 6, 2026! The stock currently trades at $19.73. Watch how the price reacts after the release. With a P/E ratio of 11.8, the market will be watching closely whether earnings meet expectations.
Is Amphastar P shorted?
Yes, Amphastar P is shorted with 19.8% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Amphastar P stock?
No, insiders are not buying Amphastar P shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 14,188 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 1,695,738 $ sold. Active sellers include Lee Howard, Zhou Rong, Zhang Jack Y. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Amphastar P a good stock?
Based on our total score, Amphastar P is rated as a mediocre stock with a total score of 56 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 91/100, Quality: 49/100, Momentum: 27/100. In addition: analysts see 11.5% upside to the price target; technical signal: Hold. Whether Amphastar P is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Amphastar P stock?
The outlook for Amphastar P based on current data: the average analyst price target is $22.00 (+11.5%); the next earnings report is due on 8/6/2026, which can move the price; the P/E ratio is 11.8 (low – a possible value stock). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Amphastar P stock moving?
Amphastar P is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 19.8% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Amphastar P go?
The average analyst price target for Amphastar P is $22.00, which corresponds to a potential gain of 11.5% from the current price of $19.73. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Amphastar P fall?
We lack enough history to give a specific floor for Amphastar P. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Amphastar P do?
Amphastar Pharmaceuticals laver og sælger medicin, mest injektioner og næsespray, i USA, Kina og Frankrig. De driver forretning ved både at udvikle nye præparater og producere generisk medicin. Amphastar er især kendt for produkter som BAQSIMI, en næsespray mod alvorligt lavt ... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Amphastar P as an investment.
Did Amphastar P raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Amphastar P. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Amphastar P making money or losing money?
Yes, Amphastar P is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 11.0% — which is solid. The operating margin (profit before interest and taxes) is 8.0%. At a P/E ratio of 11.8, you currently pay 11.8 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Amphastar P go bankrupt?
The bankruptcy risk of Amphastar P is rated as low. Altman Z2 (a model for assessing financial distress) is 4.65 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 115% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Amphastar P have a lot of debt?
Amphastar P has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 115%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Amphastar P service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 2.5x, and net debt equals 2.6 years of earnings (EBITDA).
